DDInter1616 DDInter875
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Romidepsin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Romidepsin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Romidepsin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Histrelin
Romidepsin {u} may lead to a major life threatening interaction when taken with {v} Bacillus calmette-guerin substrain tice live antigen
Romidepsin {u} may lead to a major life threatening interaction when taken with {v} Halofantrine
Romidepsin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Romidepsin may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Romidepsin may lead to a major life threatening interaction when taken with Halofantrine